Literature DB >> 31197460

[Hot topic: direct oral anticoagulants (DOAC) in antiphospholipid syndrome?]

C Specker1, T Dörner2, M Schneider3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31197460     DOI： 10.1007/s00393-019-0657-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  5 in total

1.  Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study.

Authors:  Scott C Woller; Scott M Stevens; David A Kaplan; Matthew T Rondina
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-12       Impact factor: 2.389

2.  EULAR recommendations for the management of antiphospholipid syndrome in adults.

Authors:  Angela Tincani; Michael M Ward; Maria G Tektonidou; Laura Andreoli; Marteen Limper; Zahir Amoura; Ricard Cervera; Nathalie Costedoat-Chalumeau; Maria Jose Cuadrado; Thomas Dörner; Raquel Ferrer-Oliveras; Karen Hambly; Munther A Khamashta; Judith King; Francesca Marchiori; Pier Luigi Meroni; Marta Mosca; Vittorio Pengo; Luigi Raio; Guillermo Ruiz-Irastorza; Yehuda Shoenfeld; Ljudmila Stojanovich; Elisabet Svenungsson; Denis Wahl
Journal:  Ann Rheum Dis       Date:  2019-05-15       Impact factor: 19.103

Review 3.  Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Authors:  Virginie Dufrost; Jessie Risse; Tatiana Reshetnyak; Maria Satybaldyeva; Yao Du; Xin-Xin Yan; Stella Salta; Grigorios Gerotziafas; Zhi-Cheng Jing; Ismaël Elalamy; Denis Wahl; Stéphane Zuily
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

4.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Authors:  Vittorio Pengo; Gentian Denas; Giacomo Zoppellaro; Seena Padayattil Jose; Ariela Hoxha; Amelia Ruffatti; Laura Andreoli; Angela Tincani; Caterina Cenci; Domenico Prisco; Tiziana Fierro; Paolo Gresele; Arturo Cafolla; Valeria De Micheli; Angelo Ghirarduzzi; Alberto Tosetto; Anna Falanga; Ida Martinelli; Sophie Testa; Doris Barcellona; Maria Gerosa; Alessandra Banzato
Journal:  Blood       Date:  2018-07-12       Impact factor: 22.113

5.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959
  5 in total
  1 in total

1.  [Antiphospholipid syndrome : Update on diagnostics and management].

Authors:  Christof Specker; Rebecca Fischer-Betz; Thomas Dörner
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.